New Agents for Acute Treatment of Migraine in Adults

January 5th, 2021 | Pharmacy Pearls•Migraine

This edition of Pharmacy Pearls reviews the new agents that have been approved for acute migraine treatment and covers important clinical information including mechanism of action, efficacy data, common drug interactions, and cost. As most available clinical trials compare these agents to placebo (not currently available therapies), we also review potential role in therapy for these new agents.

As always, we welcome any questions or feedback you may have. Just email the Pharmacy Team.

Taking too long?

Reload document

Open in new tab

Download PDF [234.33 KB]

135 Corporate Woods, Suite 320
Rochester, New York 14623-1466

Phone: (585) 758-7823
Fax: (585) 424-1268

Website by:

This is not an offer to purchase or a solicitation of an offer to purchase any securities or interest in Accountable Health Partners, LLC (AHP). An offer will only be made by means of a confidential private placement memorandum and subscription agreement.

ABI Value	Interpretation	Recommendation
Greater than 1.4	Calcification/vessel hardening	Refer to vascular specialist
1.0 - 1.4	Normal	None
0.9 - 1.0	Acceptable	None
0.8 - 0.9	Some arterial disease	Treat risk factor
0.5 - 0.8	Moderate arterial disease	Refer to vascular specialist
Less than 0.5	Severe arterial disease	Refer to vascular specialist

New Agents for Acute Treatment of Migraine in Adults

New Agents for Acute Treatment of Migraine in Adults

COVID-19Ongoing Updates

COVID-19
Ongoing Updates